On May 21, 2026, in Stockholm, a recent study published in Nature Communications reveals that capillary blood samples collected remotely can effectively measure Alzheimer's disease biomarkers linked to cognitive decline and function in older individuals. This breakthrough offers promising implications for early detection and monitoring of the disease. The study highlights the potential benefits of utilizing this method for diagnosing Alzheimer's, potentially impacting the lives of millions worldwide.